

# Research Journal of Pharmaceutical, Biological and Chemical Sciences

## Docking and Cytotoxicity Test on Human Breast Cancer Cell Line (T47d) of *N*-(Allylcarbamothioyl)-3-chlorobenzamide and *N*-(Allylcarbamothioyl)-3, 4-dichlorobenzamide.

Siswandono, Tri Widiandani\*, and Suko Hardjono.

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Airlangga Surabaya, Indonesia.

### ABSTRACT

The specific objective of this research is to investigate the biological activity of thiourea derivatives by in silico study and the cytotoxicity test on human breast cancer cell lines. In this present study, the molecular docking of the new compound *N*-(allylcarbamothioyl)-3-chlorobenzamide (BATU-02) and *N*-(allylcarbamothioyl)-3,4-dichlorobenzamide (BATU-04) were evaluated on EGFR (1M17.pdb) using MVD v5.5 and showed that the re-rank scores of BATU-02 and BATU-04 are smaller than 5-fluorouracil (5-FU). From the docking result, we can predict that the compounds have a higher biological activity. The cytotoxicity test were evaluated on human breast cancer cell lines (T47D) using MTT assay. Relevant result showed that these compounds (BATU-02 and BATU-04) demonstrated are more potent compared to 5-FU as the commercial anticancer drug, with respective  $IC_{50}$  were 128  $\mu\text{g}/\text{mL}$  (BATU-02); 86  $\mu\text{g}/\text{mL}$  (BATU-04); and 213  $\mu\text{g}/\text{mL}$  (5-FU). It can be concluded that the modification compounds of thiourea can be further developed as a potential anticancer drug.

**Keywords:** Docking, thiourea, cytotoxicity, T47D, 1M17

\*Corresponding author

## INTRODUCTION

Cancer is one of the leading causes of death in the world and it is becoming a severe problem in the world of wellness. The success of cancer treatment is a challenge in the 21<sup>st</sup> century, so it underlines the most urgent to develop novel and safe chemotherapeutic agents with greater anticancer [1].

In the development of anticancer drugs, especially to obtain a better activity, it is performed modification of the structure of thiourea derivatives [2-4]. Thiourea derivatives constitute one class of anticancer promising for further development. This derivative work as inhibitors of EGFR to inhibit receptor tyrosine kinases (RTKs) in the intracellular region [5]. In addition, thiourea can also serve as a conjugate of the anti-EGFR monoclonal antibody[6,7].

In this study, the compounds have been made by reacting allylthiourea with benzoyl chloride derivatives (3-chloro and 3,4-dichloro) to form the compound *N*-(allylcarbamothioyl)-3-chlorobenzamide (BATU-02) and *N*-(allylcarbamothioyl)-3,4-dichlorobenzamide[9]. To predict the anticancer activity of the compounds, it is conducted in silico (docking) test using Molegro Virtual Docker version 5.5 that uses epidermal growth factor receptor (EGFR) kinase with pdb code 1M17, i.e. a receptor model of erlotinib constituting EGFR a receptor inhibitor [5,10].

The BATU-02 and BATU-04 are investigated for cytotoxicity activity in human breast cancer cell line (T47D) [12, 15]. The cytotoxicity test is determined through MTT method or 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide. IC<sub>50</sub> is determined based on 50% T47D cells alive. For comparability, it is used 5-fluorouracyl, an anticancer compound that has been used clinically for the treatment of cancer.

## MATERIALS AND METHODS

### In Silico

**Materials:** A computer (HP, core i7), Epidermal Growth Factor Receptor (1M17.pdb).

**Method:** The docking method is using Molegro Virtual Docker version 5.5. The docking began with a preparation on EGFR receptor with 1M17 code taken from the Protein Data Bank. The test ligand was prepared by making the 2-D and the 3-D structure of the compound using ChemBioOffice program Ultra 11.0 and its energy was minimized using MMF94. The resulted in Rerank Score describing the minimal energy required by the compound in interaction with the receptor [9].

### In Vitro

**Materials:** (*N*-(allylcarbamothioyl)-3-chlorobenzamide (BATU-02), *N*-(allylcarbamothioyl)-3,4-dichlorobenzamide (BATU-04), 5-fluorouracyl (Sigma, USA); DMSO (Sigma, USA); *Rosewell Park Memorial Institute* (RPMI) 1640; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide]= MTT (Sigma, USA); *Fetal Bovine Serum* (FBS) 10% (Gibco, USA).

**Method:** The Cytotoxicity assay was determined in vitro using cell lines T47D using the MTT method. This method required four test groups, namely the compound (A), a positive control (B), a control cell (C), and a control medium (D). It was prepared seven concentrations obtained from stratified dilution with RPMI medium (1000; 500; 250; 125; 62.5; 31.25; 15.625) µg/mL. T47D cell culture was prepared in the microplate of 96 wells, with a density of 5 x 10<sup>3</sup> cells/well.

### MTT assay


The assay was carried out following Mossman method [16] with modification in stopper reagent. T47D cells were distributed into 96 well plates, then were incubated for 24 hours under CO<sub>2</sub>. Test solutions in the series of concentrations were added, then the mixtures were incubated again for 24 hours. At the final stage of incubation, to each well was added MTT in PBS, then incubation was continued for 4 hours at 37 °C until formazan was formed. MTT reaction was stopped by addition of stopper reagent (SDS 10% in 0.01N HCl)

followed by overnight incubation at room temperature. Absorbance was read with an ELISA reader at 595 nm. The absorbance was converted to percentage of living cells (cell viability) [17].

## RESULTS AND DISCUSSION

### Docking

The result of preparing the structure of 2-Dimensional and 3-Dimensional of the *N*-(allylcarbamoithioyl)-3-chlorobenzamide (BATU-02), *N*-(allylcarbamoithioyl)-3,4-dichlorobenzamide (BATU-04) using ChemBio3D Ultra 11.0 program is shown in Figure 1 [12].



**Figure 1: The structure of 2-Dimensional and 3-Dimensional of the *N*-(allylcarbamoithioyl)-3-chlorobenzamide (BATU-02), *N*-(allylcarbamoithioyl)-3,4-dichlorobenzamide (BATU-04) of which the energy has been minimized using MMFF94.**

Docking results of 5-FU and BATU-02 and BATU-04 on EGFR kinase (1M17.pdb) can be seen in Table 1 [13].

**Table 1: Docking Results of 5-FU and BATU Derivatives**

Compound Code	Rerank Score
BATU-02	-94.4187
BATU-04	-93.1137
5-FU	-48.9354

From the docking results, the Rerank Score of all BATU derivatives is smaller than the Rerank Score of 5-FU. This suggests that the modified compound has smaller bond energy and so that the binding is more stable [14]. Thus, the modified compound can be expected to have greater biological activity by *in silico* test.

The overview of the amino acids involved in the interaction process of compounds between BATU-02 and BATU-04 versus EGFR is presented in Figure 2 [13].

### Cytotoxicity Assay

Cell viability is converted from the absorbance of formazan formed after MTT treatment. Percentage of living cells (cell viability) after treatment of test compounds in different concentrations are presented in Table 2.




Figure 2: The amino acids involved in the interaction process of compounds between BATU-02 (A) and BATU-04 (B) and EGFR kinase (1M17)




Figure 3: The cells viability overlay profile of 5-FU and BATU-02 and BATU-04

To provide clearer pictures on the influence of different concentrations of 5-FU and BATU-02 and 04 on cell viability, the data is plotted as profiles of cell viability as can be seen in Figure 3. It is obvious that cell viability is getting decreased as the concentration of 5-FU and BATU-02 and BATU-04 increased.

Table 2: T47D cells viability (%) after treatment at various concentrations

Compound	The percentage of living cells T47D (%) at various concentrations						
	15.625 µg/mL	31.25 µg/mL	62.5 µg/mL	125 µg/mL	250 µg/mL	500 µg/mL	1000 µg/mL
BATU-02	96.86±1.26	88.23±2.67	82.86±13.89	50.29±31.49	30.94±13.02	12.10±1.98	14.19±2.61
BATU-04	103.97±9.35	90.73±1.96	88.22±4.97	10.84±0.48	13.42±1.43	13.17±0.11	16.82±1.92
FU	61.70±7.98	54.23±4.07	52.91±2.66	52.85±4.58	46.58±4.96	39.41±2.19	27.28±1.05

Table 3: IC<sub>50</sub> of the test compounds on T47D

Compound	IC <sub>50</sub> (µg/mL)
BATU-02	128±11.0
BATU-04	86±3.6
FU	213±2.2

The results of probit analysis to obtain the score of IC<sub>50</sub> BATU-02; 04 and 5-FU as a comparison can be seen in Table 3.

Based on the cytotoxicity results on IC<sub>50</sub>, it has been known that *N*-(allylcarbamothioyl)-3-chlorobenzamide (BATU-02) and *N*-(allylcarbamothioyl)-3,4-dichlorobenzamide (BATU-04) have higher cytotoxicity activity compared with 5-fluorouracil. This result is linear with *in silico* approach. Therefore, these compounds are feasible to be developed as a potential anticancer drug.

### CONCLUSION

Based on the results of this study can be concluded that the new compounds of thiourea derivatives (BATU-02 and BATU-04) can be further developed as a potential anticancer drug.

### ACKNOWLEDGEMENTS

This experiment was supported in part by a grant from the *Ministry of Research, Technology, and Higher Education, Republic of Indonesia* and the Faculty of Pharmacy Universitas Airlangga.

### REFERENCES

- [1]. Liu, W., Zhou, J., Zhang, T., Zhu, H., Qian, H., Zhang, H., Huang, W., Gust, H., 2012, Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents, *Bioorganic & Medicinal Chemistry Letter*, Volume 22: 3701-2704.
- [2]. Li, H.Q.; Lv, P.C.; Yan, T.; Zhu, H.L., 2009, Urea derivatives as *anticancer agents*. *Anticancer Agents Med Chem.*, Volume 9: 471-480
- [3]. Li, H.Q, Yan, T., Ying, Y., Shi, L., Zhou, C. F., Zu, H.L., 2010, Synthesis and structure-activity relationship of *N*-benzyl-*N*-(*X*-2-hydroxybenzyl)-*N'*-phenylureas and thioureas as antitumor agents, *Bioorganic & Medicinal Chemistry*, Volume 18: 305-313.
- [4]. Huang, X.C., Wang, M., Pan, Y.P., Yao, G.Y., Wang, H.S., Tiang, X.Y., Qin, J.K., Zhang, Y., 2013, Synthesis and antitumor activities of novel thiourea  $\alpha$ -aminophosphonates from dehydroabiatic acid, *European Journal of Medicinal Chemistry*, Volume 69: 508-520.
- [5]. Yang, W., Hu, Y., Yang, Y.S., Zhang, F., Zhang, Y.B., Wang, X.L., Tang, J.F., Zhong, W.Q., Zhu, H.L., 2013, Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents, *Bioorganic & Medicinal Chemistry*, Volume 21: 1050-1063.
- [6]. Reymond, M. Reilly, 2010, *Monoclonal Antibody and Peptide Targeted Radiotherapy of Cancer*. Wiley and Sons, ISBN: 1118035151.
- [7]. Ingargiola, M., Dittfield, C., Runge, R., Zenker, M., Heldt J. M., Steinbach, J., Cordes, N., Baumann, M., Kotzerke, J., Schughart, K. L. A., 2012, Flowcytometric Cell-Based Assay to Preselect Antibody Construct for Radionuclide Conjugation. *Journal of The International Society for Advancement of Cytometry*, Volume 81A: 865-873
- [8]. Siswandono, 2014, *Pengembangan Obat Baru*, Airlangga University Press, Surabaya, pp: 1-17.
- [9]. Widiandani, T., Siswandono, 2014, Modifikasi Struktur dan Prediksi Aktivitas Antikanker Senyawa Baru Turunan Aliltiourea Secara *In Silico*, e-jurnal Berkala Ilmiah Kimia Farmasi, Vol 4:1.
- [10]. Li, H.Q., Yan, T., Ying, Y., Shi, L., Zhou, C.F., Zu, H.L., 2010, Synthesis and structure-activity relationship of *N*-benzyl-*N*-(*X*-2-hydroxybenzyl) -*N'*-phenylureas and thioureas as antitumor agents, *Bioorganic & Medicinal Chemistry*, Volume 18: 305-313.
- [11]. Zampieri, L., Bianchi, P., Ruff, P., and Arbuthnot, P., 2002, Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells, *Anticancer Res.*, Volume 22(4): 2253-9.
- [12]. CambridgeSoft, 2008, *CamBioDraw Ultra 11 for Tutorial*, All Right Reserved.
- [13]. CLCbio, 2012, *Molegro Virtual Docker User Manual, MVD 2012.5.5 for Windows, Linux, and Mac OS X*, Molegro – A CLC bio company.
- [14]. Young, D.C., 2009, *Computational Drug Design, A Guide for Computational and Medicinal Chemists*. New York: John Wiley and Sons.
- [15]. Widiandani, T., Arifianti, L., and Siswandono, 2016. Docking, Synthesis and Cytotoxicity Test on Human Breast Cancer Cell Line (t47d) of *N*-(Allylcarbamothioyl)Benzamide, *International Journal of*



- Pharmaceutical and Clinical Research, Vol 8 (5), 372-376.
- [16]. Mosmann T. Rapid colorimetric assay for cellular growth & survival: application to proliferation & cytotoxicity assays. J Immunol Methods 1983;65:55-63.
- [17]. Marcellino, R., Widiandani, T., and Syahrani, A., 2015. Some Benzoxazine And Aminomethyl Derivatives Of Eugenol: Cytotoxicity On MCF-7 Cell Line. International Journal Of Pharmacy and Pharmaceutical Sciences 7 (5): 229-232.